Satoshi Otsu

489 total citations
24 papers, 187 citations indexed

About

Satoshi Otsu is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Satoshi Otsu has authored 24 papers receiving a total of 187 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 10 papers in Surgery and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Satoshi Otsu's work include Colorectal Cancer Treatments and Studies (7 papers), Cancer Treatment and Pharmacology (4 papers) and Helicobacter pylori-related gastroenterology studies (4 papers). Satoshi Otsu is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Cancer Treatment and Pharmacology (4 papers) and Helicobacter pylori-related gastroenterology studies (4 papers). Satoshi Otsu collaborates with scholars based in Japan, United States and Vietnam. Satoshi Otsu's co-authors include Shuichi Hironaka, Koichiro Watanabe, Akira Nishizono, Toshio Fujioka, Tomohiro Nishina, Ryotaro Morinaga, Hiroki Hara, Toshihiko Doi, Satoru Iwasa and Morihiro Watanabe and has published in prestigious journals such as Journal of Clinical Oncology, Infection and Immunity and Annals of Oncology.

In The Last Decade

Satoshi Otsu

22 papers receiving 186 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Satoshi Otsu Japan	8	79	70	54	47	38	24	187
Heewon Kwak South Korea	9	76 1.0×	103 1.5×	118 2.2×	32 0.7×	43 1.1×	12	275
Caroline Rossoni France	6	113 1.4×	44 0.6×	39 0.7×	49 1.0×	56 1.5×	12	200
Kuniyasu Irie Japan	11	61 0.8×	191 2.7×	119 2.2×	20 0.4×	22 0.6×	33	281
Camtu D. Truong United States	7	87 1.1×	135 1.9×	78 1.4×	23 0.5×	51 1.3×	18	264
Chia-Long Lee Taiwan	9	56 0.7×	124 1.8×	65 1.2×	20 0.4×	86 2.3×	12	319
Joselyn Sanchez Peru	8	187 2.4×	48 0.7×	41 0.8×	63 1.3×	45 1.2×	14	269
Graziana Gallo Italy	6	45 0.6×	44 0.6×	65 1.2×	12 0.3×	36 0.9×	23	158
Arnoud H. A. M. van Oijen Netherlands	7	125 1.6×	205 2.9×	162 3.0×	18 0.4×	53 1.4×	7	300
Suh Eun Bae South Korea	9	49 0.6×	247 3.5×	209 3.9×	23 0.5×	47 1.2×	18	342
Fang‐Yu Chao Taiwan	9	61 0.8×	162 2.3×	22 0.4×	61 1.3×	80 2.1×	11	353

Countries citing papers authored by Satoshi Otsu

Since Specialization

Citations

This map shows the geographic impact of Satoshi Otsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Satoshi Otsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Satoshi Otsu more than expected).

Fields of papers citing papers by Satoshi Otsu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Satoshi Otsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Satoshi Otsu. The network helps show where Satoshi Otsu may publish in the future.

Co-authorship network of co-authors of Satoshi Otsu

This figure shows the co-authorship network connecting the top 25 collaborators of Satoshi Otsu. A scholar is included among the top collaborators of Satoshi Otsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Satoshi Otsu. Satoshi Otsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tanaka, Ryota, Yosuke Suzuki, Takashi Inagaki, et al.. (2025). Impact of Cancer Cachexia Progression on OATP1B1 Transport Activity: Quantitative Analysis Using Coproporphyrin‐I as an Endogenous Biomarker. Clinical Pharmacology & Therapeutics. 118(1). 128–137.

Tsushima, Takahiro, Yasuhiro Tsubosa, Akifumi Notsu, et al.. (2024). First-line FOLFOX therapy for advanced esophageal squamous cell carcinoma: Multicenter prospective study in Japan.. Journal of Clinical Oncology. 42(3_suppl). 280–280. 1 indexed citations

Otsu, Satoshi & Shuichi Hironaka. (2023). Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal Cancer. Cancers. 15(18). 4564–4564. 5 indexed citations

Hashimoto, Tadayoshi, Satoshi Otsu, Shuichi Hironaka, et al.. (2023). Phase II biomarker identification study of anti-VEGF agents with FOLFIRI for pretreated metastatic colorectal cancer. Future Oncology. 19(23). 1593–1600. 4 indexed citations

Komori, Azusa, Satoshi Otsu, Mototsugu Shimokawa, et al.. (2023). Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study. International Journal of Clinical Oncology. 28(8). 1073–1081. 1 indexed citations

Kasai, Takashi, Kiyoshi Mori, Yoichi Nakamura, et al.. (2023). Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non‐squamous, non‐small cell lung cancer: TORG (thoracic oncology research group) 1321. Cancer Medicine. 12(14). 14988–14999. 3 indexed citations

Nishikawa, Kazuo, Shuichi Hironaka, Takashi Inagaki, et al.. (2022). A multicentre retrospective study comparing site-specific treatment with empiric treatment for unfavourable subset of cancer of unknown primary site. Japanese Journal of Clinical Oncology. 52(12). 1416–1422. 2 indexed citations

Shibuki, Taro, Toshihiko Mizuta, Mototsugu Shimokawa, et al.. (2022). Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab–paclitaxel or FOLFIRINOX: A post–hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study). BMC Cancer. 22(1). 19–19. 7 indexed citations

Otsuka, Taiga, Mototsugu Shimokawa, Satoshi Otsu, et al.. (2019). A multicenter retrospective study of gemcitabine plus nab-paclitaxel or FOLFIRINOX in metastatic pancreatic cancer: NAPOLEON study. Annals of Oncology. 30. iv17–iv18. 5 indexed citations

10.

Doi, Toshihiko, Satoru Iwasa, Kei Muro, et al.. (2018). Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial. Gastric Cancer. 22(4). 817–827. 49 indexed citations

11.

Satoh, Taroh, Tadamichi Denda, Tetsuya Hamaguchi, et al.. (2017). A phase II study of ziv-aflibercept (Z) + FOLFIRI in Japanese patients (pts) with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 35(4_suppl). 707–707. 1 indexed citations

12.

Watanabe, Koichiro, Satoshi Otsu, Yoshinori Hirashima, et al.. (2016). A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 77(6). 1157–1164. 27 indexed citations

13.

Sakai, Daisuke, Hiroya Taniguchi, Takao Tamura, et al.. (2014). Randomized phase II study of panitumumab (Pmab) plus irinotecan (CPT-11) versus cetuximab (Cmab) plus CPT-11 in patients with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) following treatment with fluoropyrimidine, CPT-11, and oxaliplatin (L-OHP) chemotherapy: WJOG6510G.. Journal of Clinical Oncology. 32(15_suppl). TPS3654–TPS3654. 2 indexed citations

14.

Otsu, Satoshi, et al.. (2013). CD34-negative solitary fibrous tumour resistant to imatinib. BMJ Case Reports. 2013. bcr2013200126–bcr2013200126. 2 indexed citations

15.

Watanabe, Koichiro, Satoshi Otsu, Ryotaro Morinaga, et al.. (2010). Vesicocutaneous fistula formation during treatment with sunitinib malate: Case report. BMC Gastroenterology. 10(1). 128–128. 7 indexed citations

16.

Morinaga, Ryotaro, Satoshi Otsu, Kenji Kashima, & Koichiro Watanabe. (2010). Extramedullary Plasmacytoma as an Uncommon Cause of Gastrorrhagia. Internal Medicine. 49(15). 1679–1680. 2 indexed citations

17.

Kodama, Masaaki, Kazunari Murakami, Tadayoshi Okimoto, et al.. (2007). Sclerosing Cholangitis with Autoimmune Pancreatitis which Resembles Cholangiocarcinoma. Nihon Naika Gakkai Zasshi. 96(11). 2525–2528.

18.

Otsu, Satoshi, Kazuyo Gotoh, Tetsu Yamashiro, et al.. (2006). Transfer of Antigen-Pulsed Dendritic Cells Induces Specific T-Cell Proliferation and a Therapeutic Effect against Long-TermHelicobacter pyloriInfection in Mice. Infection and Immunity. 74(2). 984–993. 22 indexed citations

19.

Murakami, Kazunari, Tadayoshi Okimoto, Masaaki Kodama, et al.. (2006). Comparison of Amoxicillin–Metronidazole Plus Famotidine or Lansoprazole for Amoxicillin–Clarithromycin–Proton Pump Inhibitor Treatment Failures for Helicobacter pylori Infection. Helicobacter. 11(5). 436–440. 20 indexed citations

20.

Minoura, Takanori, Seiichi Kato, Satoshi Otsu, et al.. (2004). Influence of age and duration of infection on bacterial load and immune responses to Helicobacter pylori infection in a murine model. Clinical & Experimental Immunology. 139(1). 43–47. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact